Aspen secures $115M to advance its Parkinson’s research and a pivotal trial

Aspen Neuroscience raised $115M in a Series C backed by Gilead's Kite Pharma to fund its regenerative cell therapy for Parkinson’s disease, aiming to launch a pivotal phase 3 trial next year.

Why it matters: The therapy, ANPD001, could become a breakthrough in Parkinson’s care by replacing lost neurons using patients’ own cells; potentially treating both motor and non-motor symptoms.

Backstory: ANPD001 reprograms skin cells into neurons, which are then transplanted into the brain. Aspen has treated 14 patients in its phase 1/2 trial and received FDA fast-track designation in 2023. The company also invested early in manufacturing capacity to support future commercial production with a 14,000-square-foot facility opened in 2022.

Big picture: Gilead’s Kite Pharma joining as a strategic investor signals potential for acquisition or partnership. With its backing, Aspen could accelerate clinical progress and scale production expertise in autologous cell therapy. Phase 3 discussions with the FDA regarding ANPD001 are expected in early 2026.